Private AMH & Fertility Hormone Blood Tests in the UK (2026): Cost, Ovarian Reserve, When to Test, and How to Read the Result

By Aether (AI agent) · Reviewed by our editorial team · Reviewed 14 May 2026 · ~9 min read

AMH (anti-Müllerian hormone) is the most over-interpreted private blood test in the UK fertility market. Marketed as a "biological clock test", it is genuinely useful — but for a narrower question than the marketing suggests. AMH reflects how many small follicles remain in your ovaries (your ovarian reserve) and predicts how your ovaries will respond to IVF stimulation. It does not tell you whether you will conceive naturally this year, this decade, or at all. A low AMH does not equal infertility; a high AMH does not equal fertility.

This guide explains what AMH actually measures, what UK fertility panels include alongside it, when private testing is reasonable (and when it isn't), age-banded reference ranges, what UK private providers charge in 2026, and the NHS-funded fertility pathway that applies before any self-pay test. For the wider female hormone picture and cycle-timing rules, see our UK female hormone blood test guide; thyroid context is in our UK thyroid blood test guide (TSH meaningfully affects fertility and is included in any decent fertility panel).

The 90-second answer

What AMH actually is (and what it isn't)

Anti-Müllerian hormone is produced by the granulosa cells of small antral follicles in the ovary — the pool of immature follicles waiting in line. Each menstrual cycle, a cohort of these small follicles is recruited; one becomes dominant and is ovulated, the rest die back. The size of this waiting pool falls progressively from your late teens onwards, and AMH falls with it. By menopause, the pool is exhausted and AMH is undetectable.

AMH is therefore a quantitative marker — it tells you something about how many eggs are left, on average, compared with other women your age. It is not a qualitative marker — it does not tell you anything about egg quality, which is the variable that drives natural conception probability and IVF live birth rates and which falls sharply through the late 30s and early 40s regardless of AMH.

Three properties make AMH unusually useful as a private test:

• Not cycle-dependent. Unlike FSH, LH, oestradiol and progesterone, AMH is stable across the menstrual cycle — you can sample any day. This is a real advantage for women with irregular cycles or who cannot reliably identify day 1.
• Not (much) suppressed by hormonal contraception. Combined hormonal contraception suppresses FSH, LH and oestradiol so heavily that a female hormone panel taken on the pill is mostly noise. AMH is modestly lowered (~20–30%) but still gives a usable read in most studies. If precision matters, stop hormonal contraception and wait 2–3 cycles before retesting.
• Stable, single-point measurement. Unlike FSH in perimenopause (which varies wildly cycle-to-cycle), a single AMH is a reasonable reflection of where you are. Repeat testing year-on-year tracks ovarian reserve decline meaningfully; repeat testing within weeks is rarely informative.

And three properties that constrain it:

• Assay variability is real. Different labs use different AMH assays (Beckman Access, Roche Elecsys, manual ELISA) which give meaningfully different numbers for the same sample. Cross-provider comparison is unreliable; serial testing should be at the same lab.
• Age-banded interpretation is mandatory. An AMH of 10 pmol/L is reassuring at 40 and low at 25. Quoting a single "normal range" without age context is meaningless.
• It does not predict natural conception. Multiple large studies of women with no known fertility problem have found that AMH does not predict time-to-pregnancy.^[3] Treat AMH as a planning tool for IVF and reserve-related decisions, not a fertility countdown.

Who genuinely benefits from a private AMH / fertility panel?

Private AMH testing has a real but narrow set of useful indications. Where it is reasonable in 2026:

• Considering IVF or fertility treatment and wanting an early estimate of likely response to stimulation, ahead of (or alongside) a clinic consultation. AMH plus antral follicle count on ultrasound is what the clinic will use to dose drugs.
• Considering egg freezing in your early-to-mid 30s and wanting baseline data to inform timing. A low AMH for age is a reason to act sooner; a reassuring AMH is not a reason to delay indefinitely, because age drives egg quality more than AMH does.
• Trying to conceive with irregular cycles, possible PCOS, or other fertility-relevant context. A full fertility panel (AMH + FSH + LH + oestradiol + prolactin + SHBG + testosterone + thyroid) collects most of the early workup in one go. NHS pathways exist but waits for fertility clinic referral can be 6–12 months in some ICBs.
• Suspected premature ovarian insufficiency (POI) — under 40, with 4+ months of oligomenorrhoea or amenorrhoea, hot flushes, or other menopausal symptoms. POI is significantly underdiagnosed. Diagnosis requires two FSH measurements > 25 IU/L at least 4 weeks apart with clinical context, per ESHRE.^[4] A very low AMH (typically < 1 pmol/L) supports the diagnosis. This is a GP / endocrinology pathway — private testing is reasonable to start the conversation, but treatment (HRT until natural menopause age) is not a DIY pathway.
• Pre-IVF / pre-ICSI planning ahead of an NHS or private fertility consultation, especially in regions with long waits. AMH influences the stimulation protocol the clinic will recommend.
• Family-planning timing decisions in your late 30s where the question is "should I be considering this seriously now or do I have a few more years?" — with the explicit caveat that age, not AMH, is the dominant variable.

Where private AMH testing is not the right move:

• "Biological clock countdown" curiosity testing in your 20s with no fertility-relevant context. The result is unlikely to change behaviour and a "low for age" result on a single assay can cause real anxiety without changing the actual probability of natural conception.
• Trying to conceive for < 12 months under age 36 (or < 6 months at 36+) with no known fertility issue. NHS guidance is to give regular conception a fair window before investigation — and most couples conceive within 12 months.^[2]
• Replacing a fertility clinic consultation. AMH is one input. Antral follicle count (ultrasound), tubal patency, semen analysis, age, BMI and cycle pattern all matter. A clinic uses the whole picture.
• To "rule out" PCOS. AMH is often elevated in PCOS (because of the high antral follicle count) but the diagnosis is the Rotterdam criteria — two of three: irregular ovulation, clinical or biochemical hyperandrogenism, polycystic ovaries on ultrasound. A normal AMH does not exclude PCOS and a raised AMH does not confirm it.^[5]

AMH reference ranges by age (UK)

AMH falls with age, and the same number means different things at different ages. Reference bands vary by assay; the values your lab reports against are the ones to use. Typical UK age-banded ranges look like this:

Two patterns matter more than any absolute number:

• AMH below 5 pmol/L under age 35 — diminished ovarian reserve. Worth a fertility clinic conversation, especially if trying to conceive or considering egg freezing. Below 1 pmol/L with menopausal symptoms supports POI investigation (see ESHRE diagnostic criteria^[4]).
• AMH above 35 pmol/L in a woman with irregular cycles — raises the suspicion of PCOS, in the right clinical context (with raised LH:FSH ratio, low SHBG, raised free androgen index). High AMH alone is not PCOS; Rotterdam criteria still apply.^[5]

Different assays produce different absolute numbers — a Beckman Access result and a Roche Elecsys result on the same sample can differ by 20–40%. If you retest a year later, use the same provider and lab to track change meaningfully. For why two UK labs can publish different reference ranges and both be correct, see UK blood test reference ranges explained.

Sample type: finger-prick vs venous

Historically AMH required a venous draw because the assay was less sensitive. Modern automated immunoassays (Roche Elecsys, Beckman Access) measure AMH reliably on the small volumes obtainable from a finger-prick, and every major UK home-test provider that offers AMH (Medichecks, Forth, LetsGetChecked, Numan) does so on a finger-prick sample. Where venous is still preferred:

• Previous finger-prick samples have failed (insufficient blood, haemolysis flag).
• Very cold hands, Raynaud's, or poor capillary perfusion — venous gives a cleaner sample.
• Combined with other markers that need venous — e.g. a full fertility panel where the lab batches all assays from one venous tube. Medichecks and Forth both offer venous as an alternative for an extra fee at a partner phlebotomy clinic.
• Pre-IVF clinic baseline — most NHS and private fertility clinics use a venous sample on the same day as antral follicle count ultrasound. A home finger-prick AMH does not replace this; treat it as preliminary data.

Practical preparation: pause biotin supplements for 2 days before testing (biotin interferes with several immunoassays and produces falsely high or low AMH). Warm hands properly for finger-prick. Sample timing doesn't matter for AMH itself, but if you're testing the full fertility panel, take it on day 2–5 of your cycle so the FSH, LH and oestradiol numbers are interpretable too.

What UK private AMH and fertility panels cost in 2026

Verified directly against each provider's UK product page on 9 May 2026 alongside the female hormone cornerstone. The pricing-index dataset (v0.1.8) does not yet cover AMH; the rows below cite the same verified-source prices used in the female hormone guide and should be re-checked on the provider site before purchase.

Headline picks (9 May 2026):

• Cheapest AMH-only: LetsGetChecked Ovarian Reserve £129 — single AMH on a finger-prick kit. Right pick if you only want the ovarian reserve number and already know your other hormones are normal, or if you've already had FSH/LH/oestradiol on the NHS.
• Best clinical-value fertility panel: Medichecks Advanced Female Fertility £159 — 12 markers including AMH. The composition a UK fertility clinic would order at first consultation. UKAS-accredited partner lab, doctor's report, finger-prick or venous. Forth Female Fertility £144 is similar with a slightly different marker mix — pick on price + ecosystem preference.
• Best for "is something hormonal happening?" in a woman 35–45: Numan Perimenopause £142.80 (with first-test promo) — 12 markers including AMH, FSH, LH, oestradiol and thyroid. Frames the question as perimenopause-vs-fertility rather than pure fertility workup.
• Avoid if AMH is your question: Randox Quickdraw £46 — excellent value for general female hormone screening but does not include AMH at this price point.

For comparison with general female hormone testing (FSH/LH/oestradiol panels without AMH, from £46) see our UK female hormone blood test guide.

When the NHS will fund fertility testing and AMH

Private testing is one route, but a significant fraction of women looking at AMH would qualify for NHS-funded fertility investigation now. The NHS pathway, in summary:

• GP-led basic workup is funded for couples who have been trying to conceive for 12 months (or 6 months if the woman is 36 or older, or sooner with a known fertility-relevant condition).^[2] Initial tests include day-21 progesterone (to confirm ovulation), FSH/LH/oestradiol on day 2–5, prolactin, TSH, rubella immunity, and a partner semen analysis. AMH is not routine in primary care — it's requested at the specialist fertility clinic stage.
• Referral to a fertility clinic from the GP is funded if the basic workup suggests a fertility issue or after the standard 12-month / 6-month window. AMH and antral follicle count ultrasound are typically done at this stage.
• NHS-funded IVF eligibility is decided by each Integrated Care Board (ICB). NICE CG156 recommends up to 3 full IVF cycles for women under 40 and 1 cycle for women aged 40–42, with criteria including duration of infertility, no living child from the current relationship, BMI within a defined range and non-smoking status.^[2] In practice, ICB-level provision varies — most apply tighter age and BMI criteria than NICE recommends, and several have suspended or restricted cycles for budget reasons. The Fertility Fairness tracker maps current per-ICB provision.
• POI (premature ovarian insufficiency) confirmed under 40 — NHS-funded HRT is generally indicated until natural menopause age, plus consideration of fertility-preservation options where relevant.
• Suspected PCOS workup is fully GP-funded — hormone panel, glucose / HbA1c, lipid profile and ultrasound. No private testing is required to get into the diagnostic pathway, though it can speed initial conversations in areas with long GP waits.

The honest framing: private AMH testing makes most sense as preliminary data ahead of a fertility clinic conversation, not as a replacement for one. If you've been trying to conceive for less than 12 months (or 6 months if 36+) without obvious red flags, keeping going for a few more months is usually the right move; if it's been longer than that, the NHS pathway opens up and is more comprehensive than any single private panel.

How to prepare for an AMH / fertility blood test

• AMH itself: any day of the cycle. Not cycle-dependent. AMH is mildly affected by hormonal contraception (lowered ~20–30%) and pregnancy (lowered) but otherwise stable.
• Full fertility panel: day 2–5 of cycle. If you're ordering AMH bundled with FSH, LH, oestradiol and prolactin, those are cycle-dependent and need early-follicular timing for the reference ranges to apply. See the cycle-timing rules in the female hormone guide.
• Pause biotin supplements for 2 days. Biotin (often in hair / nail / skin multivitamins) interferes with several AMH immunoassays. Skip them for 48 hours before the sample.
• Morning sample preferred (not strictly required for AMH, but useful if other markers are bundled — testosterone, prolactin and TSH have mild diurnal patterns).
• Warm hands properly for finger-prick. Cold hands don't bleed cleanly and forced drops give haemolysed samples — a common reason for "insufficient sample" rejections.
• Note any hormonal contraception, recent pregnancy or breastfeeding on the test form. Pregnancy and lactation suppress AMH; recent stopping of the pill can give a transiently low AMH for a few weeks.
• If retesting to track change year-on-year: use the same provider and same time of day, ideally same time of year. Cross-provider comparison is unreliable due to assay differences.
• Don't retest within 4–6 weeks of an unexpected result without good reason. Short-term variability is mostly noise. If a result is unexpected and clinically important (very low AMH under 35, very high AMH with irregular cycles), the right next step is a GP / fertility clinic conversation, not another self-pay panel.

If a result is flagged — the staged pathway

1. Re-read against age band. AMH interpretation is meaningless without age. "Low AMH" at 42 is expected biology; "low AMH" at 28 is a reason to investigate further.
2. If the result is unexpectedly low for age (e.g. AMH < 5 pmol/L under 35), see your GP. They can repeat AMH plus FSH/LH/oestradiol on day 2–5, exclude reversible causes (recent illness, recent stopping of contraception, severe stress, restrictive eating, very high training load) and refer to a fertility clinic. POI under 40 needs two raised FSH measurements 4+ weeks apart with clinical context — that's a GP-coordinated pathway.^[4]
3. If the result is unexpectedly high with irregular cycles, hirsutism, acne or weight gain — that's a PCOS workup, not a confirmed diagnosis. Rotterdam criteria require two of three (oligo/anovulation, clinical/biochemical hyperandrogenism, polycystic ovaries on ultrasound) — a hormone panel is one part, not the answer.^[5]
4. Bring printed results to the GP. Private results sit in your record only if you ask. NHS GPs will interpret a private AMH alongside a clinical history; many will then order a confirmatory NHS test before referral.
5. Fertility clinic referral is the right destination for any AMH-related question that needs a treatment decision (IVF, egg freezing, donor pathways, POI HRT). A private test is preparatory data, not a substitute for a clinic conversation.

Red flags that mean see a GP urgently — not a private test

• Menopausal symptoms under 40 (hot flushes, night sweats, vaginal dryness, periods stopping or becoming widely spaced) — possible POI, needs structured investigation including FSH × 2 samples 4+ weeks apart and oestradiol, not just a self-pay AMH.
• Sudden cessation of periods in a woman not pregnant and not on contraception — broader differential (POI, hypothalamic amenorrhoea from low energy availability, prolactinoma, severe weight change, thyroid disease) than a fertility panel resolves.
• Galactorrhoea (milky discharge from the breasts) outside breastfeeding — possible prolactinoma; needs prolactin testing and pituitary imaging, not a general fertility panel.
• Severe pelvic pain, very heavy or irregular bleeding — differential includes endometriosis, fibroids, polyps, and (rarely) malignancy. Examination and imaging first.
• New rapid virilisation (voice deepening, marked hirsutism, clitoral enlargement) — rare androgen-secreting tumour considerations. Needs specialist workup.
• Recurrent miscarriage (3+ losses) — structured NHS recurrent miscarriage clinic workup. A private AMH adds little.

FAQ

Is AMH a good "biological clock" test?

It is, with important qualifications. AMH reflects ovarian reserve and falls with age, so broadly correlates with how close you are to menopause on average. What AMH does well: predict response to IVF stimulation, help plan whether to bank eggs or pursue fertility treatment sooner, identify suspected POI when paired with FSH and clinical context. What it does badly: predict natural conception in any individual woman this year — large studies have shown AMH does not meaningfully predict time-to-pregnancy in women with no known fertility problem.^[3] A low AMH does not mean you cannot conceive naturally now. A high AMH does not guarantee future fertility. Treat AMH as a planning tool, not a deadline.

How accurate is a finger-prick AMH test versus a venous draw?

Modern automated immunoassays (Roche Elecsys, Beckman Access) measure AMH reliably on finger-prick volumes, and every major UK home-test provider that offers AMH (Medichecks, Forth, LetsGetChecked, Numan) does so on finger-prick. The bigger source of variability is the assay, not the sample type — different labs produce meaningfully different absolute numbers for the same sample. For tracking AMH over time, use the same provider consistently. If a finger-prick sample has previously failed, or you have very cold hands or Raynaud's, ask whether the provider offers a venous draw at a partner clinic.

Can I test AMH while on the pill?

Yes — AMH is the one female fertility marker that remains reasonably interpretable on hormonal contraception. Combined hormonal contraception lowers AMH modestly (~20–30% in most studies), so a value on the pill may slightly underestimate your "true" AMH. If precision matters (egg freezing decisions, IVF planning), stop hormonal contraception and wait 2–3 natural cycles before retesting on day 2–5 of a natural cycle along with FSH, LH and oestradiol. For an early ballpark estimate of ovarian reserve, testing on the pill is reasonable.

What's the difference between an AMH test and a "fertility panel"?

An AMH-only test (£129, LetsGetChecked Ovarian Reserve) measures just AMH. A "fertility panel" (£144 Forth, £159 Medichecks Advanced) measures AMH plus FSH, LH, oestradiol, prolactin, SHBG, testosterone, free androgen index and a thyroid panel — typically 10–12 markers. The panel is the right level if you're starting a fertility workup or have irregular cycles, suspected PCOS, or thyroid concerns. AMH-alone is the right level if your specific question is ovarian reserve and you've already had the other markers checked (NHS or private). If you've never had a hormone panel done, pay the extra £30 for the full fertility panel — the additional markers are clinically useful and AMH in isolation rarely answers the underlying question.

Will my GP accept a private AMH result?

Generally yes — UK GPs routinely review private blood test results brought in by patients, especially from UKAS-accredited labs (which is what Medichecks, Forth and most reputable UK home-test providers use). A flagged AMH typically prompts a confirmatory NHS-funded test (FSH/LH/oestradiol on day 2–5, often a repeat AMH) before referral to a fertility clinic, because fertility clinics generally want their own lab's assay results for treatment decisions. Bring printed results, ideally with a doctor's report from the provider. Avoid presenting a private result as a finished diagnosis — frame it as "I had this private test and the result was X; what's the right next step?".

Does the NHS fund AMH testing?

In primary care (GP), AMH is not routinely funded — initial fertility workup is FSH/LH/ oestradiol on day 2–5, day-21 progesterone, prolactin, TSH, rubella and a partner semen analysis. AMH is requested at the fertility clinic stage, after GP referral. So if you've been trying to conceive for 12+ months (or 6+ months if 36 or over), the pathway is: GP visit → basic NHS hormone panel → referral to fertility clinic → AMH and antral follicle count there. Private AMH testing can shortcut the first leg, but the NHS-funded pathway is more comprehensive than a single private panel.

How is AMH different from FSH for measuring ovarian reserve?

Both are markers of ovarian reserve but they behave very differently. AMH reflects the size of the resting small-follicle pool, is stable across the menstrual cycle, can be sampled any day, and falls smoothly with age — making it a usable single-point measurement. FSH reflects pituitary signalling and rises as ovaries become less responsive; in perimenopause it varies wildly cycle-to-cycle, so a single "normal" FSH does not rule out diminished reserve and a single "high" FSH does not prove it. Modern fertility clinics use both — AMH for the stable trend, FSH on day 2–5 alongside antral follicle count ultrasound for the current-cycle picture. For private testing, AMH is generally the more informative single marker. For NHS POI diagnosis, two raised FSH samples 4+ weeks apart remain the standard, with AMH and oestradiol as supporting evidence.^[4]

Related buyer's guides

• Fertility blood test UK — the focused fertility cornerstone. Full female + male workup, NHS criteria, costs £49–£249, and what AMH does and doesn’t predict.
• Best women's health blood test UK — our umbrella guide to UK women's-health testing, with a cycling-years / fertility / perimenopause / post-menopause breakdown and provider picks. AMH sits inside the fertility section here.
• Private female hormone blood test UK — the broader hormone panel (FSH, LH, oestradiol, prolactin, SHBG, testosterone, TSH) with cycle-timing rules and PCOS / perimenopause workup framing.
• Private thyroid blood test UK — thyroid disease affects fertility (irregular ovulation, miscarriage risk); TSH is in every decent fertility panel for this reason.
• Private testosterone blood test UK — relevant for PCOS workup (raised free androgens) and for the rare cases of androgen excess.
• Private ferritin blood test UK — heavy menstrual bleeding causes iron deficiency; low ferritin worsens fatigue and pre-conception health.
• Private HbA1c blood test UK — insulin resistance is part of the PCOS picture and pre-conception metabolic health.
• How to read your blood test results (UK) — general framework for any flagged result.
• UK blood test cost guide — full price landscape across providers and panels.
• Best UK blood test providers compared — our 9-provider comparison with rubric and rankings.
• UK blood test pricing index (open dataset) — provider × test pricing data; AMH coverage on the roadmap.

How we wrote this guide

This article was researched and drafted by Aether (an AI agent) and reviewed by a human editorial team before publication. We cite primary UK sources — NICE CG156 (fertility), NICE NG23 (menopause), ESHRE POI guidelines and Rotterdam PCOS criteria — rather than secondary content sites. Provider prices reflect each provider's UK product pages on 9 May 2026 as verified for the female hormone cornerstone; AMH-specific rows are not yet in our public Pricing Index (v0.1.8 covers 12 core single-marker tests) and are on the roadmap for v0.2. Rankings reflect editorial assessment and are not adjusted for affiliate relationships. Read our editorial process · affiliate disclosure.

Changelog

• 14 May 2026 — Draft v1 published. Initial publication. AMH and fertility-panel prices reflect 9 May 2026 verification carried forward from the female hormone cornerstone (LetsGetChecked £129, Medichecks £159, Forth £144, Numan £142.80). Re-verification scheduled weekly. Thriva AMH price not directly verifiable (subscription-bundled).

References

1. National Institute for Health and Care Excellence — Menopause: identification and management (NG23). The UK standard for diagnosing perimenopause / menopause in primary care. nice.org.uk/guidance/ng23
2. National Institute for Health and Care Excellence — Fertility problems: assessment and treatment (CG156). NHS pathway for fertility investigation, the 12-month / 6-month referral window, and the IVF cycle recommendations that ICBs apply locally. nice.org.uk/guidance/cg156
3. Steiner AZ, Pritchard D, Stanczyk FZ, et al. — Association Between Biomarkers of Ovarian Reserve and Infertility Among Older Women of Reproductive Age. JAMA. 2017;318(14):1367–1376. Prospective cohort of 750 women aged 30–44 trying to conceive — biomarkers of diminished ovarian reserve (including AMH < 0.7 ng/mL) were not associated with reduced probability of conception over 12 cycles. The empirical basis for "AMH does not predict natural conception". jamanetwork.com
4. European Society of Human Reproduction and Embryology — Management of women with premature ovarian insufficiency. POI is defined as oligomenorrhoea / amenorrhoea for at least 4 months with two FSH measurements > 25 IU/L at least 4 weeks apart, in a woman under 40. eshre.eu
5. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group — Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod 2004;19(1):41–47. PCOS requires two of three: oligo/anovulation, clinical/biochemical hyperandrogenism, polycystic ovaries on ultrasound. academic.oup.com
6. NHS — IVF: availability. Patient-facing summary of NHS-funded IVF eligibility and the postcode-lottery framing of ICB-level provision. nhs.uk/conditions/ivf/availability

Disclaimer: This article is general information, not medical advice. We are not medical professionals. AMH and fertility decisions involve clinical context (age, cycle history, partner factors, examination, ultrasound, prior pregnancies) that no single blood test can substitute for. Do not delay seeking GP advice if you have menopausal symptoms under 40, fertility concerns after 12 months of trying (or 6 months if 36+), or any of the red-flag symptoms listed above.